Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr 1:16:293.
doi: 10.1186/s12889-016-2958-4.

Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012

Hana Orlíková  1 , Marek Malý  2 , Pavla Lexová  3 , Helena Šebestová  2 , Radomíra Limberková  4 , Lucie Jurzykowská  3 , Jan Kynčl  3   5
Affiliations

Protective effect of vaccination against mumps complications, Czech Republic, 2007-2012

Hana Orlíková et al. BMC Public Health. .

Abstract

Background: In the Czech Republic, two-dose immunization against mumps achieves 98% coverage. The routine reporting detects mumps cases, clinical complications, and hospital admissions in unvaccinated but also in vaccinated individuals. Using surveillance data of patients with mumps we assessed the effectiveness of mumps vaccination on mumps clinical complications and hospitalization need. We also investigated the effect of the time since immunization.

Methods: We analysed data on incident mumps cases reported to the Czech national surveillance system in 2007-2012. Using a logistic regression model with adjustment for age, sex, year of onset, and the administrative region, the association between vaccination and the most frequent mumps complications and hospitalization was evaluated. The adjusted odds ratios (ORa) for mumps complications were compared between the vaccinated and non-vaccinated groups, reflecting the vaccine effectiveness (VEa) computed as VEa = (1-ORa) × 100. We estimated the risk of mumps complications by the time from vaccination.

Results: From total of 9663 mumps analysed cases 5600 (58%) occurred in males. The mean age at the disease onset was 17.3, median 16 years. Ninety percent of the study patients had no complications, while 1.6% developed meningitis, 0.2% encephalitis, and 0.6% pancreatitis. Mumps orchitis occurred in 659 (11.8%) male cases. In total, 1192 (12.3%) patients required hospitalization. Two doses of vaccine received by 81.8% cases significantly reduced the risk of hospitalization: ORa 0.29 (95% CI: 0.24, 0.35). Two doses showed statistically significant VEa 64% (95% CI: 46, 79) for meningitis, 93% (95% CI: 66, 98) for encephalitis in all cases, and 72% (95% CI: 64, 78) for orchitis in males. Vaccine effectiveness for orchitis declined from 81 to 74% and 56% in the most affected age groups 10-14, 15-19, and 20-24 years, respectively. Among 7850 two-dose recipients, the rate of complications rose from below 1 to 16% in categories up to 6 years and 24 and more years after the second dose, respectively.

Conclusions: This study demonstrates a significant preventive effect of two-dose vaccination against mumps complications (orchitis, meningitis, or encephalitis) and hospitalization for mumps. The risk of complications increases with time interval from vaccination. Teenagers and young adults were the most affected age groups.

Keywords: Hospitalization; Mumps; Mumps complications; Orchitis; Surveillance; Vaccination.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Relationship between time from the second vaccine dose to mumps onset and age at the second dose, by complications
Fig. 2
Fig. 2
Relationship between probability of complications and time from the second dose
See this image and copyright information in PMC

References

    1. Plotkin SA, Rubin SA: Mumps vaccine. In: Plotkin SA, Orenstein WA, Offit PA. Vaccines. 5th ed. Philadelphia: W.B. Saunders Elsevier Inc.; 2008. p. 435-465
    1. Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371(9616):932–44. doi: 10.1016/S0140-6736(08)60419-5. - DOI - PubMed
    1. McLean HQ, Hickman CJ, Seward JF. World Health Organization, Department of Immunization, Vaccines and Biologicals. The Immunological Basis for Immunization Series. Module 16: Mumps. Geneva: World Health Organization; 2010.
    1. Beran J, Havlik J, Vonka V: Parotitis epidemica – mumps. In: Vaccination – past, present, future. Galen; 2005. p. 63-65. [in Czech]
    1. Tsoucalas G, Laios K, Karamanou M, Androutsos G. The Thasian epidemic of mumps during the 5th century BC. Infez Med. 2013;21(2):149–50. - PubMed

Publication types

MeSH terms